Stock Spotlight: Percheron Therapeutics (ASX: PER)

Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company developing novel therapies for hard-to-treat cancers and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting VISTA, an immune checkpoint that can help tumours evade the body's immune response.

With HMBD-002 progressing to a Phase II clinical trial, and an exclusive license to develop, manufacture and sell HMBD-002, Percheron Therapeutics is attracting attention from investors looking for speculative biotech stocks which may offer significant potential upside. 

Hear more from Percheron Therapeutics Ltd and Sharewise’s stock experts at our  Stocks and Sips Perth event.

About Percheron Therapeutics Limited​

Percheron Therapeutics Ltd takes promising early-stage drug candidates through clinical development. The company was originally established in 2000 as Antisense Therapeutics Ltd, a Melbourne-based biotech focused on neuromuscular and inflammatory conditions. After trials for Avicursen (ATL1102), failed to show desired efficacy, it repositioned to immuno-oncology, rebranded as Percheron Therapeutics in 2023, and switched from ANP to PER on the ASX in 2024. 



Today, Percheron Therapeutics is advancing HMBD-002, an experimental treatment designed to block VISTA, an immune checkpoint involved in suppressing immune activity around tumours. HMBD-002 was discovered by Hummingbird Bioscience and licensed exclusively to Percheron in 2025. If successful, HMBD-002 may have applications across a variety of cancers with tumour burden, including breast, lung, ovarian and pancreatic cancer. A Phase I trial has been completed and Phase II is being prepared for enrolment in late 2026.

Why Investors Are Watching ASX: PER

Percheron Therapeutics offers ASX investors a speculative opportunity that could offer highly leveraged returns linked to the commercial potential of HMBD-002, but also carries the high risk typical of an early-stage biotechnology company. The PER ASX share price​ is impacted by investor sentiment, with volatility driven by clinical trial successes,  funding, regulation and Percheron Therapeutics news.

Investor interest increased in 2026 following new HMBD-002 Phase I trial data presented at the American Association for Cancer Research (AACR) Annual Meeting, showing HMBD-002 was generally safe and well tolerated. With potential drug application across many types of cancer and the possibility of combining with other treatment drugs for greater efficacy, there is renewed investor interest in ASX: PER. 

What Makes Percheron Therapeutics Limited a Strong Investment Choice?

Percheron Therapeutics is most likely to appeal to speculative investors interested in the dynamic biotechnology sector, where successful clinical development could create outsized value from a relatively small market capitalisation.

Pipeline leverage at the right time

• HMBD-002 has already passed through a first-in-human Phase I study, providing safety and preliminary data, before its planned Phase II development.
• As a clinical-stage biotech, positive trial results or development milestones could have an outsized positive effect on the PER ASX share price.
• With HMBD-002 progressing into Phase II in 2026 and data presented at the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASC), developments at Percheron are likely to catch heightened investor interest this year.
  
  

Broad immuno-oncology opportunity

• HMBD-002 targets VISTA rather than a mutation unique to one cancer, potentially giving the drug applications across multiple solid tumours in difficult-to-treat cancers. The Phase I study included patients with pancreatic, colorectal, breast, lung, renal cell and other cancers.
• Preclinical research has also suggested potential synergy between HMBD-002 and PD-1 inhibitors such as pembrolizumab, creating the possibility of future combination-treatment strategies.

Key Stats

Source: Market Index. Data as of 26/08/26.

Growth Potential

• Progress of HMBD-002 into Phase II: After completing a Phase I clinical trial, Percheron aims to commence Phase II in the second half of 2026. A promising Phase II result may significantly increase investor interest in ASX: PER.
• Potential across multiple cancers: HMBD-002 may have applications across multiple difficult-to-treat cancers with solid tumours, making the potential market for the drug broad.
• Combination immunotherapy: Pre-clinical findings suggest HMBD-002 may work effectively alongside PD-1 inhibitors, potentially creating opportunities for combined immunotherapy treatments.
• Exclusive license: Percheron holds an exclusive worldwide licence for the development, manufacture and commercialisation of HMBD-002 across all territories and uses. 
• Strengthened funding position: In April 2026, Percheron raised ~$2.2 million, providing working capital expected to advance HMBD-002 through to 2027. Favourable Phase II trial results may help with the securing of further funding.
• Potential partnership opportunities: Successful Phase II results could encourage partnerships with larger pharmaceutical companies and accelerate global commercialisation.

Upcoming innovations from ASX:PER

The key near-term catalyst for Percheron Therapeutics is the planned commencement of Phase II clinical trials of HMBD-00 in the second half of 2026. While the Phase I study produced safety and tolerability data and encouraging biological signals, the drug's anti-cancer effectiveness remains unproven. 

The Phase II study may provide a clearer indication of which cancer or tumour types offer the strongest opportunity for HMBD-002. A promising trial result will likely enhance the ability to secure further funding for ongoing testing and development, increase commercial partnering prospects, and have a positive impact on Percheron Therapeutics’ share price.

ASX: Percheron Therapeutics Shares Returns & Investor Sentiment

As an early-stage drug developer, the valuation of PER on the ASX is impacted by investor sentiment around the probability of future clinical and commercial success. This is different to biotech or pharmaceutical companies with established revenue streams. A success or setback in clinical trials can have a substantial impact on the Percheron Therapeutics share price.

This was demonstrated in December 2025 when Percheron announced negative results from its ATL1102 study, further clinical trials were abandoned, and the PER share price fell. 

Since then, Percheron has refocused on  HMBD-002 and achieved promising Phase I results. Investor sentiment is likely to remain closely tied to further clinical developments and Percheron’s funding position.

Investment Tips For Buying Percheron Therapeutics Limited (ASX: PER)

As an early-stage drug developer, Percheron Therapeutics is best viewed as a high-risk, speculative biotech investment. It is currently loss-making and does not generate revenue, but instead offers potentially significant growth prospects through successful drug applications. ASX: PER may suit investors with a higher risk profile, or as part of a diversified portfolio that includes lower risk or income-producing stocks.

For valuation purposes, interested investors should monitor clinical trial results, regulatory factors, funding requirements, potential stock dilution and the company's cash position.  Sharewise tracks these factors and provides investment insights and buy/sell recommendations to its members. Hear from Sharewise and Percheron executives at our Stocks and Sips Perth 2026 event.

Key risks

• Clinical trial risk: HMBD-002 remains an investigational drug. While Phase I produced positive safety data it has not yet demonstrated meaningful efficacy in cancer treatment.
• Regulatory risk: Regulatory requirements can delay or prevent clinical trials, drug development or commercialisation.
• Funding and cash runway risk: Percheron relies on external funding to finance development. Further clinical trials are likely to increase expenditure and may require additional capital.
• Dilution risk: Future equity raisings could increase the number of shares on issue and dilute existing shareholders.
• Drug development risk: Developing a new medicine is a lengthy and expensive process, and drug candidates can fail despite promising early-stage results.
• Competition risk: HMBD-002 is competing with other approaches to cancer treatment, including other emerging immunotherapy possibilities.
• Commercialisation risk: Even if HMBD-002 demonstrates clinical benefit, Percheron would still need to establish manufacturing capability and develop commercial pathways before generating revenue.
• Concentration risk: Percheron’s other focus drug, Avicursen, was discontinued following negative trial results, leaving Percheron currently dependent on the success of HMBD-002.
  
  

Frequently Asked Questions

Stay informed on ASX:GMD and the wider market developments by subscribing to the Sharewise newsletter.